BCMA Multiple Myeloma

Major microbiome disruption and Toxicities Following Idecabtagene Vicleucel in Multiple Myeloma patients

Muzaffar Qazilbash, Professor of Medicine at UT- MD Anderson Cancer Center, shared a post on X:

“Major microbiome disruption was associated with toxicities following ide-cel administration in patients with multiple myeloma.”

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Authors: Satabdi Saha et al.

Idecabtagene Vicleucel

Abdur Rehman cancer Chia-Chi Chang Christine Peterson Christopher R. Flowers Donna M Weber Doris K. Hansen Elizabeth J. Shpall Faezeh Darbaniyan Frederick L. Locke Hans C. Lee idecabtagene vicleucel Krina K. Patel Lubna Rehman Mahmoud R Gaballa Marco L. Davila Mark R. Tanner Meghan Menges Melody Becnel Michael D. Jain Muzaffar Qazilbash Neeraj Y Saini OncoDaily Oncology Reetakshi Arora Robert R Jenq Robert Z. Orlowski Salvatore Corallo Satabdi Saha Sattva S. Neelapu Sheeba K. Thomas